Navigation Links
Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
Date:11/2/2007

in the placebo group than in the treated arms of this study. Safety is an important aspect of new HCV therapies, because the current standard of care is not always as well tolerated as desired."

The R7128 scientific presentation will be available for download in PDF format following the conference in the "R7128 Presentations & Publications" section of Pharmasset's website at http://www.pharmasset.com/pipeline/R7128-publications.asp.

R7128 Phase 1 Multiple Ascending Dose Study Overview

The Phase 1 clinical trial is a multiple center, observer-blinded, randomized and placebo-controlled study was conducted in 40 patients chronically-infected with HCV genotype 1 who previously failed interferon therapy. The primary objective was to assess the safety, tolerability and pharmacokinetics of R7128 after once-daily (QD) or twice-daily (BID) dosing for 14 days. The secondary objective was to assess antiviral activity by measuring the change in HCV RNA.

R7128 Safety Summary

R7128 was generally safe and well tolerated, and all patients completed the study. There were no serious adverse events, no adverse events requiring dose modification, no dose-related gastrointestinal adverse events and no clinically significant changes in hematologic or other laboratory parameters. The preliminary data on adverse events (AEs) reported shows the highest incidence of AEs was in the placebo group with 34 events in 7 of 8 patients receiving placebo. During treatment in patients receiving R7128, most of the AEs reported were of mild intensity. Eighteen AEs were reported in 7 of 8 subjects that received 750mg QD, 6 AEs in 3 of 8 subjects receiving 1500mg QD, 13 AEs in 4 of 8 subjects receiving 750mg BID and 14 AEs in 4 of 8 subjects receiving 1500mg BID. The most frequently reported AEs for patients receiving R7128 were headache (13), dry mouth (3), nausea (2), fatigue (2), tiredne
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
3. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
4. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
5. Monogram Presents Results of First ETag Breast Cancer Studies
6. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
7. Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis
8. Combination Therapy More Effective Than Monotherapy for Treating Migraine
9. Rural Canadians travel far for specialists: study
10. A new study surpasses Gene Therapy Hurdle
11. Tomato Sauce reduces Cancer Risk- Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... NC (PRWEB) , ... September 03, 2015 , ... ... August 31, 2015: DiabetesSisters is pleased to announce the additional of Carol Wysham, ... 2015 by current board members Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the complete ... Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... responsibilities which can impact the delicate life balance between work and leisure to ... - Jeffrey R. Leaptrott, CEO , A LifeMinder Plus® Emergency Care Document Set ...
(Date:9/3/2015)... ... September 03, 2015 , ... AvePoint, the established leader in ... Pack (SP) 4 – AvePoint’s solution for facilitating two-way collaboration and external sharing ... Trend-Setting Product”. This is the fifth consecutive year an AvePoint product has made ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mum n Me is pleased to announce the ... extra-large size that gives maximum protection from sun exposure, wind, bugs, and germs. The ... deliver non-slip assurance by keeping the cover securely in place. The new car seat ...
Breaking Medicine News(10 mins):Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:Mum n Me Announces New Baby Car Seat Cover 2
... (Nasdaq: MSON ), a developer of minimally ... used for the ablation of tumors and worldwide for ... the 22nd Annual Symposium on Advanced Wound Care and ... TX, April 26-29, 2009, and is widely regarded as ...
... Scientists believe the case could be the first of its kind ... might be the first case of its kind, a new report ... who died last year of meningoencephalitis, apparently after being bitten by ... to be the first reported human illness from the virus, although ...
... 13 Surgical Care Affiliates ("SCA") today announced that ... a.m. Eastern Time on Tuesday, May 19, 2009, to ... http://www.newscom.com/cgi-bin/prnh/20080812/CLTU111LOGO ) Please go to ... passcode for the conference call or contact Kathleen Vojta ...
... Reports Diluted EPS of $0.19, Operating Cash Flow of ... Flow; Company Updates 2009 Outlook to Reflect Year-to-Date Sales ... Foods Market, Inc. (Nasdaq: WFMI ) today ... 12, 2009. Sales for the quarter were $1.9 ...
... dementia , , WEDNESDAY, May 13 (HealthDay News) -- Researchers ... for developing Alzheimer,s disease in older people. , But ... complex physiological testing, may not be practical for clinical use. ... such as age and mental status exams. We do those ...
... -- Jiangbo,Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" ... Genesis Pharmaceuticals Enterprises,Inc., OTC Bulletin Board: GNPH), a ... People,s Republic of China, today announced that,the Company ... Eastern on Tuesday, May,19, 2009 to discuss financial ...
Cached Medicine News:Health News:Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care 2Health News:Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care 3Health News:Man Dies of Brain Inflammation Caused by Deer Tick Virus 2Health News:Man Dies of Brain Inflammation Caused by Deer Tick Virus 3Health News:Whole Foods Market Reports Second Quarter 2009 Results 2Health News:Whole Foods Market Reports Second Quarter 2009 Results 3Health News:Whole Foods Market Reports Second Quarter 2009 Results 4Health News:Whole Foods Market Reports Second Quarter 2009 Results 5Health News:Whole Foods Market Reports Second Quarter 2009 Results 6Health News:Whole Foods Market Reports Second Quarter 2009 Results 7Health News:Whole Foods Market Reports Second Quarter 2009 Results 8Health News:Whole Foods Market Reports Second Quarter 2009 Results 9Health News:Whole Foods Market Reports Second Quarter 2009 Results 10Health News:Whole Foods Market Reports Second Quarter 2009 Results 11Health News:Whole Foods Market Reports Second Quarter 2009 Results 12Health News:Whole Foods Market Reports Second Quarter 2009 Results 13Health News:Whole Foods Market Reports Second Quarter 2009 Results 14Health News:Whole Foods Market Reports Second Quarter 2009 Results 15Health News:Whole Foods Market Reports Second Quarter 2009 Results 16Health News:Whole Foods Market Reports Second Quarter 2009 Results 17Health News:Whole Foods Market Reports Second Quarter 2009 Results 18Health News:Whole Foods Market Reports Second Quarter 2009 Results 19Health News:Whole Foods Market Reports Second Quarter 2009 Results 20Health News:Whole Foods Market Reports Second Quarter 2009 Results 21Health News:15-Point Test Gauges Alzheimer's Risk 2Health News:Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009 2
(Date:9/2/2015)... MONROVIA, Calif. , Sept. 2, 2015 STAAR ... and marketer of implantable lenses and delivery systems for the ... William P. Wall to the Company,s Board. ... Abrams Capital, a Boston -based investment firm, ... member of the Board of Directors, and chair of the ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has ... China (Basel, Switzerland - November 26-27, 2015)" conference to ... detailed overview of the key areas of pharmaceutical regulatory affairs ... , Macau and ... All important aspects of gaining and maintaining a successful Marketing ...
(Date:9/2/2015)... , Sept. 2, 2015 Amgen ... of a Marketing Authorization Application (MAA) to the ... for etelcalcetide (formerly AMG 416) for the treatment ... chronic kidney disease (CKD) on hemodialysis therapy. If ... that can be administered intravenously. Etelcalcetide ...
Breaking Medicine Technology:William P. Wall Appointed to STAAR Surgical Board of Directors 2Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7
...   Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: ... wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") ... a marketing and distribution agreement with Asian American ... to distribute and sell Clotamin in 1,200 AACSA ...
... Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel ... has completed its previously announced sale of an aggregate ... warrants to purchase an additional 2,512,500 shares of common ... share.  The total gross proceeds from the registered direct ...
Cached Medicine Technology:Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores 2Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores 3Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering 2Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering 3
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
... Deviation Splint uses safe, mild to moderate ... deviation at the MP joints. Dorsal-based splint ... and ulnar polycentric hinges located at the ... Padded, malleable finger rings can be individually ...
Medicine Products: